Larimar Therapeutics, Inc
Price
FilingsNewest: 8-K, Director or officer changeSep 29 →Insiders13 insiders bought $25.6M in 7 open-market buys. No sales.→HoldersDeerfield 34.3%Blue Owl Capital 8.8%BlackRock 5.5%→Financing →PeersClosest companies: PEPG, VRDN, MBX→
From the filings
Figures
- Net income
- −$172.6Mlast 12 months
- Operating cash flow
- −$131.3Mlast 12 months
- Cash and equivalents
- $92.7Mat the last balance sheet
- Shares outstanding
- 103.9M shareson issue